Stay updated with breaking news from Robert giugliano. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
March 02, 2021 The lower dose of edoxaban (Savaysa; Daiichi-Sankyo) evaluated in ENGAGE AF-TIMI 48 provides a net clinical benefit, according to a new analysis of the trial, suggesting it may be useful for some patients with atrial fibrillation (AF). The trial evaluated two doses of the direct oral anticoagulant (DOAC) versus warfarin 60 and 30 mg once daily; both could be cut in half in patients meeting certain criteria. The rate of a net clinical outcome incorporating stroke/systemic embolism, major bleeding, or death was significantly lower in patients who received the lower- versus higher-dose regimen (7.26% vs 8.01%; HR 0.90; 95% CI 0.84-0.98). However, there was a trade-off with the lower dose it was associated with a greater risk of stroke/systemic embolism compared with the higher dose but with reduced risks of major, intracranial, GI, and life-threatening bleeding. ....
Understanding stroke and heart disease in women remains a major research priority Understanding the sex differences in cardiovascular disease presentation and outcomes remains a major research priority demonstrated by the record number of submissions for this year s Go Red for Women® special issue of the American Heart Association s flagship journal Circulation, published online today. Circulation editors said more than 100 manuscripts were submitted this year, the most ever in the five years in which the current editorial board has published the special issue. Undeniably, cardiovascular disease remains the number one killer of women around the world, taking the lives of 1 in 3 women. Even one life lost is too many, because we know much of heart disease and stroke is preventable and treatable.Support for ongoing research, as well as female participation in pivotal clinical trials, are imperative to effectively address sex disparities in heart disease and stroke ....
Knowing Heart Disease, Stroke in Women Remains Research Priority medindia.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medindia.net Daily Mail and Mail on Sunday newspapers.
E-Mail DALLAS, Feb. 15, 2021 Understanding the sex differences in cardiovascular disease presentation and outcomes remains a major research priority demonstrated by the record number of submissions for this year s Go Red for Women® special issue of the American Heart Association s flagship journal Circulation, published online today. Circulation editors said more than 100 manuscripts were submitted this year, the most ever in the five years in which the current editorial board has published the special issue. Undeniably, cardiovascular disease remains the number one killer of women around the world, taking the lives of 1 in 3 women. Even one life lost is too many, because we know much of heart disease and stroke is preventable and treatable, said ....